Neurocrine Biosciences NBIX Net margin
Net margin at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on trailing twelve months.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's net margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's net margin?
- Neurocrine Biosciences (NBIX) reported net margin of 21.6% in Q1 2026.
- How has Neurocrine Biosciences's net margin changed year-over-year?
- Neurocrine Biosciences's net margin increased by 70.0% year-over-year, from 12.7% to 21.6%.
- What is the long-term trend for Neurocrine Biosciences's net margin?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's net margin has grown at a -16.9% compound annual growth rate (CAGR), from 123.9% to 59.2%.
- What does net margin mean?
- The share of every sales dollar that becomes bottom-line profit.
- How do you interpret net margin?
- Higher is better, but net margin mixes operating performance with financing and tax effects and one-off items — read it alongside operating margin to separate the operating story from the rest.
- How does net margin compare across companies?
- Comparable across peers but sensitive to leverage and tax structure; two operationally identical firms can show different net margins purely from financing.